Is Bio-Techne (TECH) overvalued or fairly valued?

MarketChacha shows Bio-Techne's valuation in context — a forward P/E of about 35.1, a price-to-book of about 5.4 — alongside its revenue and profit growth and whether reported profit converts into operating cash, so you can judge value for yourself. MarketChacha does not issue ratings, price targets, or buy/sell advice.

What is the share price of Bio-Techne (TECH)?

Bio-Techne last traded at $71.71 (+0.1% on the day), as of 7/22/2026 — a delayed quote shown for education, not investment advice.

Bio-Techne

TECH · NASDAQ · Healthcare · United States

$71.71+0.1%

Delayed · as reported by Yahoo Finance · as of Jul 22, 2026, 5:19 PM

Snapshot

TickerTECH

ExchangeNASDAQ

SectorHealthcare

IndustryBiotechnology

CountryUnited States

Employees3,100

HeadquartersMinneapolis, United States

Market cap$11.2B

P/B5.4

Volume1.1M

Websitewww.bio-techne.com

Filings tracked0

About Bio-Techne

Bio-Techne Corporation, together with its subsidiaries, develops, manufactures, and sells life science reagents, instruments, and services for the research, diagnostics, and bioprocessing markets worldwide. The company operates through two segments, Protein Sciences, and Diagnostics and Spatial Biology. The Protein Sciences segment develops and manufactures biological reagents used in various aspects of life science research, diagnostics, and cell and gene therapy, such as cytokines and growth factors, antibodies, small molecules, tissue culture sera, and cell selection technologies. This segment also offers proteomic analytical tools for automated western blot and multiplexed ELISA workflow consists of manual and automated protein analysis instruments and immunoassays for use in quantifying proteins in various biological fluids. The Diagnostics and Genomics segment develops and manufactures diagnostic products, including controls, calibrators, and diagnostic assays for regulated diagnostics market, exosome-based molecular diagnostic assays, advanced tissue-based in-situ hybridization assays for spatial genomic and tissue biopsy analysis, and genetic and oncology kits for research and clinical applications; and sells products for genetic carrier screening, oncology diagnostics, molecular controls, and research, as well as instruments and process control products for hematology, blood chemistry and gases, and coagulation controls and reagents used in various diagnostic applications. The company was formerly known as Techne Corporation and changed its name to Bio-Techne Corporation in November 2014. Bio-Techne Corporation was incorporated in 1976 and is headquartered in Minneapolis, Minnesota.

Profile as reported by Yahoo Finance.

Who owns it

Insiders0.3%
Institutions99.7%
Public & other0.0%

799 institutional holders

As reported by Yahoo Finance.

Top holders

Blackrock Inc.7.83%
Vanguard Capital Management LLC6.50%
Morgan Stanley5.45%
FMR, LLC5.05%
Vanguard Portfolio Management LLC4.14%
State Street Corporation3.75%
Wellington Management Group, LLP3.27%
Geode Capital Management, LLC3.27%

Largest institutional holders, as reported by Yahoo Finance (as of 3/31/2026).

What's expected next

Next quarter

Rev $291.4M · EPS 0.44

Est. earnings growth +5.0%

Next fiscal year

Rev $1.3B · EPS 2.05

Est. earnings growth +6.6%

Analyst consensus estimates — not the company's own guidance. As reported by Yahoo Finance.

$43.2052-wk range$72.16

Delayed · as reported by Yahoo Finance

New to these terms?

P/E ROE ROCE Margins Market cap

Browse the Learn hub →

Ask MarketChacha about TECH

Get a cited, plain-English answer — the “why”, not just data. Finance research only, never buy/sell advice.

In the news

Education and discussion only — not investment advice. Financials from official filings (SEC/BSE) and reported company statements; market figures (delayed · as reported by yahoo finance) are delayed and shown for reference only. Verify with the linked sources before acting.